WO2001078725A3 - Modified release formulations containing a hypnotic agent - Google Patents

Modified release formulations containing a hypnotic agent Download PDF

Info

Publication number
WO2001078725A3
WO2001078725A3 PCT/NL2001/000299 NL0100299W WO0178725A3 WO 2001078725 A3 WO2001078725 A3 WO 2001078725A3 NL 0100299 W NL0100299 W NL 0100299W WO 0178725 A3 WO0178725 A3 WO 0178725A3
Authority
WO
WIPO (PCT)
Prior art keywords
hypnotic
modified release
pellet
pellets
agent
Prior art date
Application number
PCT/NL2001/000299
Other languages
French (fr)
Other versions
WO2001078725A2 (en
Inventor
Johannes Jan Platteeuw
Den Heuvel Dennie Johan Ma Van
Dalen Frans Van
Jacques Maria Lemmens
Original Assignee
Synthon Bv
Johannes Jan Platteeuw
Den Heuvel Dennie Johan Marijn
Dalen Frans Van
Jacques Maria Lemmens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv, Johannes Jan Platteeuw, Den Heuvel Dennie Johan Marijn, Dalen Frans Van, Jacques Maria Lemmens filed Critical Synthon Bv
Priority to EP01923989A priority Critical patent/EP1272181A2/en
Priority to AU50661/01A priority patent/AU5066101A/en
Publication of WO2001078725A2 publication Critical patent/WO2001078725A2/en
Publication of WO2001078725A3 publication Critical patent/WO2001078725A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Abstract

Hypnotic pharmaceutical compositions are made from pellets and exhibit a modified release. Zolpidem or a pharmaceutically acceptable salt thereof is a typical hypnotic. The pellets are preferably spherical and exhibit a dissolution profile that includes 60 % of the hypnotic agent being release from the pellet not earlier than 5 minutes from the start of a specified in vitro dissolution test. Although the modified release profile can include 50 % of the hypnotic agent being released not earlier than 15 minutes after the start of the dissolution test, the pellet preferably does not contain a release rate controlling excipient or coating. Instead, microcrystalline cellulose and the active constitute the majority of the pellet, e.g. 90 % or more. Spherical pellets are also made by a convenient method that is applicable to any pharmaceutically active agent.
PCT/NL2001/000299 2000-04-13 2001-04-12 Modified release formulations containing a hypnotic agent WO2001078725A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01923989A EP1272181A2 (en) 2000-04-13 2001-04-12 Modified release formulations containing a hypnotic agent
AU50661/01A AU5066101A (en) 2000-04-13 2001-04-12 Modified release formulations containing a hypnotic agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19693900P 2000-04-13 2000-04-13
US60/196,939 2000-04-13

Publications (2)

Publication Number Publication Date
WO2001078725A2 WO2001078725A2 (en) 2001-10-25
WO2001078725A3 true WO2001078725A3 (en) 2001-12-20

Family

ID=22727371

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2001/000299 WO2001078725A2 (en) 2000-04-13 2001-04-12 Modified release formulations containing a hypnotic agent

Country Status (4)

Country Link
US (2) US6638535B2 (en)
EP (1) EP1272181A2 (en)
AU (1) AU5066101A (en)
WO (1) WO2001078725A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9125868B2 (en) 2006-11-09 2015-09-08 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
US9457005B2 (en) 2005-11-22 2016-10-04 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803240D0 (en) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SK9292002A3 (en) * 1999-12-28 2002-10-08 Ajinomoto Kk Oral preparations for diabetes
US7811557B1 (en) * 2000-10-27 2010-10-12 Viacell, Inc. Methods for improving central nervous system functioning
WO2003011228A2 (en) 2001-08-01 2003-02-13 Biogal Gyogyszergyar Rt Purification and crystalline forms of zaleplon
GB0121436D0 (en) * 2001-09-04 2001-10-24 Pfizer Ltd Biomodulated multiparticulate formulations
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20030165566A1 (en) * 2002-01-10 2003-09-04 O'toole Edel Sedative non-benzodiazepine formulations
EP1941878A1 (en) * 2002-01-10 2008-07-09 Biovail Laboratories International Srl Sedative non-benzodiazepine formulations
WO2003059349A1 (en) * 2002-01-10 2003-07-24 Biovail Laboratories Inc. Sedative non-benzodiazepine formulations
PL373694A1 (en) * 2002-02-15 2005-09-05 Teva Gyogyszergyar Reszvenytarsasag Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom
CA2483827C (en) * 2002-04-29 2012-01-24 Amir H. Shojaei Pharmaceutical formulations with improved bioavailability
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
AU2003251627A1 (en) * 2002-06-27 2004-01-19 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
MXPA04012923A (en) * 2002-06-27 2005-03-31 Sb Pharmco Inc Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment.
AU2003249010A1 (en) * 2003-01-13 2004-08-10 Dainippon Pharmaceutical Co., Ltd. Process for the preparation of 1,2-dichloroethane free crystals of zonisamide and the highly pure crystals of zonisamide
US7375111B2 (en) 2003-04-29 2008-05-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
SI3395339T1 (en) * 2003-09-12 2019-08-30 Amgen, Inc, Rapid dissolution formulation of a cinacalcet hcl
ATE493981T1 (en) * 2003-11-04 2011-01-15 Supernus Pharmaceuticals Inc ONCE DAILY DOSAGE FORMS OF TROSPIUM
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
EP1691789B1 (en) * 2003-11-25 2017-12-20 SmithKline Beecham (Cork) Limited Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
WO2005051383A1 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
PL1691811T3 (en) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
KR20140104986A (en) * 2004-02-17 2014-08-29 트랜스셉트 파마슈티칼스, 인코포레이티드 Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
KR100582350B1 (en) * 2004-02-17 2006-05-22 한미약품 주식회사 Tamsulosin hydrochloride composition for oral administration and controlled-release granule formulation thereof
JP2008500288A (en) * 2004-05-28 2008-01-10 イメイジノット ピーティーワイ エルティーディー Oral therapeutic compound delivery system
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
GB0423800D0 (en) * 2004-10-27 2004-12-01 Orexo Ab New pharmaceutical formulations
EP1913935A1 (en) * 2005-01-21 2008-04-23 Teva Pharmaceutical Industries Ltd Stable pharmaceutical formulations of zonisamide and methods for their manufacture
ES2344574T3 (en) * 2005-01-21 2010-08-31 Teva Pharmaceutical Industries Ltd STABLE PHARMACEUTICAL FORMULATIONS OF ZONISAMIDE AND PROCEDURES FOR PREPARATION.
US20070123562A1 (en) * 2005-05-25 2007-05-31 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the-night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20070020333A1 (en) * 2005-07-20 2007-01-25 Chin-Chih Chiang Controlled release of hypnotic agents
UA89684C2 (en) 2005-07-20 2010-02-25 Панасеа Биотек Лтд. Two-layer pharmaceutical dosed out form with modified liberation of nimesulide
US20070098788A1 (en) * 2005-10-28 2007-05-03 Gore Subhash P Non-benzodiazepine hypnotic compositions
ES2383330T3 (en) * 2005-11-28 2012-06-20 Orexigen Therapeutics, Inc. Zonisamide Sustained Release Formulation
EP3263117A1 (en) * 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
AR056633A1 (en) * 2005-12-07 2007-10-17 Gador Sa PHARMACEUTICAL COMPOSITIONS OF HYPNOTIC AGENTS OF SHORT ACTION IN THE FORM OF A MODIFIED RELEASE AND THE PROCEDURES TO PREPARE SUCH FORMULATIONS
WO2007069061A2 (en) * 2005-12-16 2007-06-21 Wockhardt Ltd Controlled release compositions containing zolpidem
RU2008139634A (en) * 2006-03-21 2010-08-27 Тева Фармасьютикл Индастриес Лтд. (Il) PHARMACEUTICAL COMPOSITION TOLTERODINE WITH CONTROLLED RELEASE
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
KR101735466B1 (en) 2006-11-09 2017-05-15 오렉시젠 세러퓨틱스 인크. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
WO2008070795A2 (en) * 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
EP1938805A1 (en) * 2006-12-22 2008-07-02 LEK Pharmaceuticals D.D. Monolithic sustained release zolpidem tablets
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US20090076066A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched zolpidem
US20090169618A1 (en) * 2007-12-26 2009-07-02 Limor Ari-Pardo Zolpidem pharmaceutical compositions
US20090269409A1 (en) * 2008-04-24 2009-10-29 Mukesh Kumar Garg Pharmaceutical compositions comprising eszopiclone
JP2011521973A (en) * 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド Methods for treating visceral fat conditions
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
WO2012064349A1 (en) * 2010-11-09 2012-05-18 Forest Carl A Sleep aid composition and method
WO2013119605A1 (en) * 2012-02-07 2013-08-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Promoting sleep using at1 receptor blockers
RS63569B1 (en) 2012-06-06 2022-10-31 Nalpropion Pharmaceuticals Llc Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
CN106806351A (en) * 2017-03-30 2017-06-09 成都绿林科技有限公司 A kind of preparation with zolpidem as main chemical compositions and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023700A1 (en) * 1993-04-22 1994-10-27 Rijksuniversiteit Gent Laboratorium Voor Farmaceutische Technologie High release solid preparation, preparation and use thereof
WO1995028147A1 (en) * 1994-04-18 1995-10-26 Basf Aktiengesellschaft Sustained-release matrix pellets and method for preparing them
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862140A (en) 1972-05-08 1975-01-21 Warner Lambert Co 4-hydroxy-2h- 1-benzothiopyran-3-carboxamide 1,1-dioxides
FR2492382A1 (en) 1980-10-22 1982-04-23 Synthelabo IMIDAZO (1,2-A) PYRIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
US4626538A (en) 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
US4753801A (en) * 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
US4640020A (en) * 1985-11-27 1987-02-03 Mcdonnell Douglas Corporation Zoned microwave drying apparatus and process
FR2600650B1 (en) 1986-06-27 1988-09-09 Synthelabo PROCESS FOR THE PREPARATION OF IMIDAZOPYRIDINES AND INTERMEDIATE COMPOUNDS
GB8705083D0 (en) * 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
ES2075403T3 (en) 1990-08-24 1995-10-01 Spirig Ag Pharmazeutische Prap PROCEDURE FOR THE MANUFACTURE OF PELLETS.
JP3623805B2 (en) * 1992-02-20 2005-02-23 ユーロセルテイツク・エス・アー Hydromorphone spheroid modified release formulation
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
IT1276522B1 (en) 1995-04-07 1997-10-31 Elena Benincasa USE OF ZOLPIDEM FOR THE THERAPEUDIC TREATMENT OF NEUROPSYCHIATRIC SYNDROMES ASSOCIATED WITH DYSFUNSION AND NEURAL CIRCUITS OF
DE19637082A1 (en) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Rapidly disintegrating pellets
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE69908546T2 (en) 1999-03-25 2004-04-29 Synthon B.V. Imidazopyridine derivatives and process for their preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023700A1 (en) * 1993-04-22 1994-10-27 Rijksuniversiteit Gent Laboratorium Voor Farmaceutische Technologie High release solid preparation, preparation and use thereof
WO1995028147A1 (en) * 1994-04-18 1995-10-26 Basf Aktiengesellschaft Sustained-release matrix pellets and method for preparing them
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457005B2 (en) 2005-11-22 2016-10-04 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9107837B2 (en) 2006-06-05 2015-08-18 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9125868B2 (en) 2006-11-09 2015-09-08 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression

Also Published As

Publication number Publication date
US20040047908A1 (en) 2004-03-11
US20030054041A1 (en) 2003-03-20
EP1272181A2 (en) 2003-01-08
AU5066101A (en) 2001-10-30
US6638535B2 (en) 2003-10-28
WO2001078725A2 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
WO2001078725A3 (en) Modified release formulations containing a hypnotic agent
IL111647A (en) Pharmaceutical compositions comprising microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles and their preparation
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
CA2330480A1 (en) Controlled release formulation of divalproex sodium
NO975872L (en) Formulations for controlled release of poorly soluble drugs
GB2264640B (en) Microcrystalline cellulose spheroids comprising hydromorphone and a sugar
NZ334914A (en) Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique
NZ333822A (en) Tramadol multiple unit formulations comprising individual pellets of trmadol coated with one or more membrane layers for controlling release
WO2001076575A3 (en) The treatment of respiratory diseases
DK0923934T3 (en) Modified release matrix formulation of cefaclor and cephalexin
ES2331046T1 (en) CONTROLLED RELEASE FORMULATION.
CA2387575A1 (en) Coating
CA2339913A1 (en) Pharmaceutical formulations and method for making
JPS5883618A (en) Tablet-shape nitrofurantoin
WO2003005967A3 (en) Dual release levodopa ethyl ester and decarboxylase in controlled release core
CA2240281A1 (en) Modified release oral pharmaceutical composition containing 5-asa and method for the treatment of bowel diseases
HK1043945A1 (en) Pharmaceutical capsule compositions containing loratadine and pseudoephedrine.
DK1501484T3 (en) Process for the preparation of tablets from pharmaceutically active substances having undesirable tableting properties, with a granulation liquid comprising microcrystalline cellulose
MXPA04003506A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease.
CA2364226A1 (en) Controlled-release compositions of betahistine
AU3071300A (en) Multiparticulate bisoprolol formulation
WO2007015270A3 (en) Novel controlled release compositions of selective serotonin reuptake inhibitors
PL355106A1 (en) Novel dispersible and soluble galenic paracetamol formulation, method for its preparation and its applications
JP2004522780A5 (en)
WO2006081779A3 (en) A pharmaceutical composition containing olanzapine as the active agent and a process for the preparation thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001923989

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001923989

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP